GET IN TOUCH
GelMEDIX Inc. is an early-stage biotechnology company committed to innovating the next generation of ocular and regenerative therapies through its proprietary hydrogel platform. GelMEDIX's programs are based upon its photo crosslinked hydrogels, originally developed by Prof. Nasim Annabi (UCLA) and Prof. Reza Dana (Mass Eye and Ear, Harvard Medical School). These hydrogels uniquely enable bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies. GelMEDIX is developing drug products for indications across the eye focused on cell-based therapies for vision restoration, intraocular sustained release of small molecules and peptides, and in situ forming bioadhesives. GelMEDIX is backed by Safar Partners and HTL Biotechnology along with leading angel investors and is currently raising a Series-A financing.
If you have general questions please email info@gelmedix.com. For finance related matters, please email finance@gelmedix.com. For hiring, please contact hr@gelmedix.com. For scientific and ordering questions, please email rd@gelmedix.com.
700 Main St North, c/o LabCentral, Cambridge, MA 02139
NEWS
HTL ANNOUNCES ITS INCUBATOR'S EQUITY INVESTMENT IN GELMEDIX, AN EARLY-STAGE BIOTECH AIMING AT REVOLUTIONIZING OCULAR AND REGENERATIVE THERAPIES
March 10, 2022